Advertisement
Data Points for Aug. 3, 2015

Data Points for Aug. 3, 2015

By Modern Healthcare  |  August 01, 2015

Data Points for the week of Aug. 3, 2015, covered the following topics: Veterans, antibiotic use, ultrasounds, drug prices, behavioral health

Radius Health appoints new CMO

Radius Health appoints new CMO

By Adam Rubenfire  |  July 29, 2015

Dr. Lorraine Fitzpatrick is the new CMO at Radius Health, a biopharmaceutical company developing therapeutics for patients with advanced osteoporosis and other serious endocrine-mediated diseases.

Gilead continues to ride the wave of hepatitis C meds in Q2

Gilead continues to ride the wave of hepatitis C meds in Q2

By Steven Ross Johnson  |  July 28, 2015

Sales of Sovaldi and Harvoni accounted for 60% of Gilead's revenue for the second quarter of 2015. The drugs have treated more than 180,000 hepatitis C patients in the U.S. and Europe since the beginning of the year, according to the company.

Gilead beats Q2 forecasts

By Associated Press  |  July 28, 2015

Gilead Sciences on Tuesday reported second-quarter earnings of $4.49 billion. On a per-share basis, the Foster City, California-based company said it had profit of $2.92. Earnings, adjusted for costs related to mergers and acquisitions and stock option expense, came to $3.15 per share.

Pfizer sales, earnings still in patent-cliff plunge

By Steven Ross Johnson  |  July 28, 2015

Pharmaceutical giant Pfizer on Tuesday reported continuing declines in sales and earnings as it girds for the loss of patent protection in Europe and Japan of Enbrel, its rheumatoid arthritis drug.

Israel's Teva buys Allergan's generic drug unit for $40.5B

By Associated Press  |  July 27, 2015

Israel's Teva Pharmaceutical Industries said Monday it is purchasing Dublin-based Allergan's generic pharmaceuticals business for $40.5 billion, in what analysts called the largest-ever acquisition by an Israeli company.

AstraZeneca sells rare cancer drug to Genzyme for $300 million

By Steven Ross Johnson  |  July 27, 2015

British pharmaceutical giant AstraZeneca plans to sell its thyroid cancer drug Caprelsa to Cambridge, Mass.-based Genzyme in a deal valued at $300 million. It's part of the company's strategy to move away from rare disease offerings and focus on key treatments.

Cholesterol drug Praluent approved by FDA

By Associated Press  |  July 24, 2015

The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades. But the drug's $14,600-a-year price tag is certain to escalate debate about the cost of breakthrough drugs.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.